Ocular Therapeutix Says FDA Talks Progressing as It Eyes AXPAXLI NDA for Wet AMD on SOL-1 Data [Yahoo! Finance]
Ocular Therapeutix, Inc. (OCUL)
Last ocular therapeutix, inc. earnings: 3/12 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ocutx.com
Company Research
Source: Yahoo! Finance
pursuing an NDA for AXPAXLI in wet AMD based on a single, well-powered pivotal study — the company says regulators have signaled openness to single-trial approvals when trials are rigorously designed. SOL-1 reportedly met its primary endpoint with robust statistical significance and a favorable safety profile (company reports no cases of endophthalmitis or vasculitis and disclosed all IOI events); Ocular also highlights OCT stability and potential single-injection disease control at nine months, plus promising HELIOS data in NPDR. Ocular plans to commercialize AXPAXLI independently, touts IP protection “ironclad till 2044,” believes its hydrogel manufacturing can scale, and argues a superiority label could support premium pricing and payer uptake. Interested in Ocular Therapeutix, Inc.? Here are five stocks we like better. Ocular Therapeutix (NASDAQ:OCUL) Executive Chairman, President, and CEO Dr. Pravin Dugel said the company is engaged in formal discussions with the U.S. Foo
Show less
Read more
Impact Snapshot
Event Time:
OCUL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OCUL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OCUL alerts
High impacting Ocular Therapeutix, Inc. news events
Weekly update
A roundup of the hottest topics
OCUL
News
- Ocular Therapeutix™ to Participate in May Scientific and Investor ConferencesGlobeNewswire
- Ocular Therapeutix™ to Host Investor Day on June 17, 2026GlobeNewswire
- Ocular Therapeutix (OCUL) Announces Additional Positive Data From the SOL-1 Phase 3 Superiority Trial of AXPAXLI [Yahoo! Finance]Yahoo! Finance
- Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Ocular Therapeutix (OCUL) had its "buy" rating reaffirmed by HC Wainwright. They now have a $21.00 price target on the stock.MarketBeat
OCUL
Earnings
- 11/4/25 - Beat
OCUL
Sec Filings
- 4/13/26 - Form 4
- 3/27/26 - Form SCHEDULE
- 2/27/26 - Form 8-K
- OCUL's page on the SEC website